Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.78 USD | -2.08% | -0.67% | +44.90% |
Financials (USD)
Sales 2024 * | 161M | Sales 2025 * | 413M | Capitalization | 3.3B |
---|---|---|---|---|---|
Net income 2024 * | -352M | Net income 2025 * | -245M | EV / Sales 2024 * | 19.6 x |
Net cash position 2024 * | 133M | Net cash position 2025 * | 251M | EV / Sales 2025 * | 7.37 x |
P/E ratio 2024 * |
-9.07
x | P/E ratio 2025 * |
-16.3
x | Employees | 557 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.7% |
Latest transcript on Iovance Biotherapeutics, Inc.
1 day | -2.08% | ||
1 week | -0.67% | ||
1 month | -20.51% | ||
3 months | +52.39% | ||
6 months | +208.38% | ||
Current year | +44.90% |
Managers | Title | Age | Since |
---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 50 | 16-09-29 |
Director of Finance/CFO | 51 | 20-12-13 | |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Merrill McPeak
BRD | Director/Board Member | 88 | 11-07-19 |
Director/Board Member | 56 | 16-06-06 | |
Michael Weiser
BRD | Director/Board Member | 61 | 18-03-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.95% | 11 M€ | -6.03% | - | |
0.93% | 1 M€ | -.--% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.11% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 11.78 | -2.08% | 4,417,687 |
24-04-29 | 12.03 | +3.35% | 4,563,057 |
24-04-26 | 11.64 | +0.87% | 2,489,561 |
24-04-25 | 11.54 | -1.45% | 3,398,958 |
24-04-24 | 11.71 | -1.26% | 2,932,120 |
Delayed Quote Nasdaq, April 30, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.90% | 3.36B | |
-19.78% | 10.81B | |
-33.46% | 2.22B | |
-14.31% | 2.16B | |
-28.86% | 1.55B | |
+25.34% | 1.04B | |
-3.28% | 746M | |
-35.33% | 425M | |
-46.53% | 405M | |
+17.30% | 378M |
- Stock Market
- Equities
- IOVA Stock